-

01:42:57 PM

GBLX Stock News

GBLX - GB Sciences Inc

05/23/22 9:04 AM

OTC : GBLX

TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit

Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are more effective when used together than singularly, as demonstrated in an animal model of the

RHEA-AI

neutral

05/12/22 9:00 AM

OTC : GBLX

TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit

Dr. Andrea Small-Howard, President and Chief

RHEA-AI

neutral

05/05/22 9:30 AM

OTC : GBLX

TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference

Dr. Andrea Small-Howard,

RHEA-AI

neutral

05/02/22 9:00 AM

OTC : GBLX

clinical trialcovid-19

FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies

Gb Sciences, Inc. (OTCQB:GBLX), a leading

RHEA-AI

neutral

04/12/22 9:00 AM

OTC : GBLX

Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, has selected the

RHEA-AI

positive

03/29/22 8:00 AM

OTC : GBLX

Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article

On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences' proprietary, time-released, oral nanoparticle technology improved the efficacy of cannabis-based

RHEA-AI

neutral

03/16/22 3:01 PM

OTC : GBLX

UPDATE: Gb Sciences Issues Shareholder Letter

Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research

RHEA-AI

neutral

03/15/22 7:00 AM

OTC : GBLX

Gb Sciences Issues Summary Shareholder Letter

Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research

RHEA-AI

neutral

03/01/22 7:00 AM

OTC : GBLX

Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and

RHEA-AI

neutral

02/01/22 7:00 AM

OTC : GBLX

Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment

RHEA-AI

positive